Management of mild cognitive impairment (MCI): The need for national and international guidelines
Open accessThe DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Abstract
Objectives: To review available evidence of pharmacological and non-pharmacological treatment for MCI and analyse information and limitations in national and international guidelines.Methods: Experts from several European countries conducted a qualitative review of the literature on MCI and treatments for MCI, as well as respective chapters in national and international guidelines on dementia/MCI. Psychotherapeutic/psychosocial treatments were excluded from the review.Results: Consensus diagnostic criteria for MCI are available, making early recognition and accurate classification of MCI subtypes possible. MCI can be identified in a primary care setting. Further corroboration and differential diagnosis should be done at specialist level. Mixed pathologies are the rule in MCI, thus a multi-target treatment approach is a rational strategy. Promising evidence has been generated for multi-domain interventions. Limited evidence is available for different pharmacological classes that have been investigated in MCI clinical trials (e.g. acetylcholinesterase inhibitors). EGb 761® improved symptoms in some clinical trials; it is the only pharmacological treatment recommended in existing guidelines for the symptomatic treatment of MCI.Conclusions: MCI is recognised as an important treatment target and some recent national guidelines have considered symptomatic treatment recommendations for MCI. However, more needs to be done, especially at an international level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · cited 2×
“…for AD at different stages, i.e. at the preclinical stage (Sperling et al. 2011), at the MCI stage (Albert et al. 2011) and at the dementia stage (McKhann et al. 2011) in recognition of the fact that the pathological process of AD affects the brain for many years before, finally, the dementia…”
BackgroundNIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 5×
“These core AD biomarkers include: cerebrospinal fluid (CSF) concentrations of amyloid beta 42 (Ab42), phospho-tau and total tau protein, medio-temporal lobe atrophy on MRI, a typical regional reduction of brain glucose metabolism on [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) and increased fibrilla…”
BackgroundInfluentialSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 2×
“…and the Alzheimer’s Association (NIA-AA) published several sets of diagnostic criteria for AD at different stages, i.e. at the preclinical stage (Sperling et al. 2011), at the MCI stage (Albert et al. 2011) and at the dementia stage (McKhann et al. 2011) in recognition of the fact that the…”
BackgroundWinblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411 · cited 2×
“In addition to a clinical diagnosis of MCI, the modified criteria proposed by the IWG and the NIA-AA include the presence of biomarkers indicative for AD pathophysiology; these criteria are commonly used in clinical practice in Europe for diagnosis and communication to MCI patients (Bocchetta et al. 2015; Bertens et a…”
BackgroundGauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60461-5 · Cited by 3,689
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572 · cited 1×
“…with MCI who tend to remain stable (i.e. do not develop dementia) (Ganguli et al. 2011), and a proportion of patients may even revert to normal (2% (Petersen et al. 2010) to 31% (Palmer et al. 2010) depending on the MCI criteria used and design of the study); reverse conversions occur mainly in…”
Background(2018) · Neurology · doi:10.1212/wnl.0000000000004826 · Cited by 2,183 · cited 4×
“Most recently, a practice guideline update summary on MCI was published by the American Academy of Neurology (AAN) (Petersen et al. 2018), and a Spanish MCI consensus document published by the Spanish Society of Geriatrics and Gerontology (SEGG) (Lopez Trigo 2017).”
BackgroundInfluentialPreclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925 · cited 3×
“…total tau protein, medio-temporal lobe atrophy on MRI, a typical regional reduction of brain glucose metabolism on [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) and increased fibrillar Ab burden assessed with amyloid PET) (Albert et al. 2011; Dubois et al. 2016; Jack et al. 2018).”
BackgroundVitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676 · cited 1×
“A better understanding of mild cognitive impairment (MCI), including its causes, underlying pathophysiological processes and earliest possible identification, has become a major public health priority (Winblad et al. 2016).”
BackgroundThe Diagnosis and Management of Mild Cognitive Impairment: A Clinical Review
Langa, K. M., & Levine, D. A. (2014) · JAMA · doi:10.1001/jama.2014.13806 · Cited by 1,337 · cited 2×
“Progression to clinically diagnosable dementia occurs at a higher rate from MCI than from normal cognition (Roberts and Knopman 2013; Langa and Levine 2014).”
BackgroundThe neuropathology of probable Alzheimer disease and mild cognitive impairment
Schneider, J. A., Arvanitakis, Z., Leurgans, S. E., & Bennett, D. A. (2009) · Annals of Neurology · doi:10.1002/ana.21706 · Cited by 935 · cited 3×
“Data from autopsy and imaging studies reveal that mixed pathologies in both probable AD and MCI are common, mainly in the elderly (Korczyn 2002; Schneider et al. 2009).”
BackgroundAging, Memory, and Mild Cognitive Impairment
Petersen, R. C., Kokmen, E., Waring, S. C., Smith, G. E., Ivnik, R. J., & Tangelos, E. G. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004717 · Cited by 888 · cited 2×
“The concept of MCI including definitions of subtypes and diagnostic criteria has been introduced and modified over time (Petersen et al. 1997).”
BackgroundClassification and Epidemiology of MCI
Roberts, R., & Knopman, D. S. (2013) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2013.07.003 · Cited by 839
Andrieu, S., Guyonnet, S., Coley, N., Cantet, C., Bonnefoy, M., Bordes, S., Bories, L., Cufi, M.-N., Dantoine, T., Dartigues, J.-F., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30040-6 · Cited by 838 · cited 2×
“…the effect of multidomain lifestyle intervention strategies on the delay and/ or prevention of cognitive decline in older individuals with differentially increased risk for further cognitive decline (Ngandu et al. 2015; Andrieu et al. 2017; Sherman et al. 2017; Anderson-Hanley et al. 2018).”
BackgroundIsmail, Z., Smith, E. E., Geda, Y., Sultzer, D., Brodaty, H., Smith, G., Agüera‐Ortiz, L., Sweet, R., Miller, D., Lyketsos, C. G., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.017 · Cited by 818 · cited 1×
“Behavioural and psychological symptoms, also referred to as neuropsychiatric symptoms (NPS), are common in MCI patients and may be associated with greater functional impairment and progression to Alzheimer’s dementia (Ismail et al. 2016).”
BackgroundImpact of multiple pathologies on the threshold for clinically overt dementia
Kapasi, A., DeCarli, C., & Schneider, J. A. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1717-7 · Cited by 739 · cited 2×
“Lewy bodies, TDP-43 and hippocampal sclerosis) are found in elderly individuals with AD pathology (Kapasi et al. 2017).”
BackgroundAbnormality of Gait as a Predictor of Non-Alzheimer's Dementia
Verghese, J., Lipton, R. B., Hall, C. B., Kuslansky, G., Katz, M. J., & Buschke, H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020441 · Cited by 690 · cited 1×
“In addition to cognitive deficits, patients with MCI can experience motor dysfunction, including deficits in gait and balance (Verghese et al. 2002).”
BackgroundDeKosky, S. T. (2008) · JAMA · doi:10.1001/jama.2008.683 · Cited by 670 · cited 2×
“The GEM (Ginkgo Evaluation of Memory) trial reported by DeKosky et al. did not support the use of EGb 761VR to reduce the risk of developing AD or all-cause dementia in elderly individuals with normal cognition or MCI (DeKosky et al. 2008).”
ResultCholinergic system during the progression of Alzheimer’s disease: therapeutic implications
Mufson, E. J., Counts, S. E., Perez, S. E., & Ginsberg, S. D. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.11.1703 · Cited by 587 · cited 6×
“Typically, for Alzheimer’s dementia, based on evidence to date, AChE-I and Ginkgo biloba are recommended for symptomatic treatment of mild to moderate dementia in most countries, as well as memantine for moderate-tosevere dementia.”
BackgroundInfluentialIs MCI really just early dementia? A systematic review of conversion studies
Bruscoli, M., & Lovestone, S. (2004) · International Psychogeriatrics · doi:10.1017/s1041610204000092 · Cited by 550 · cited 2×
“…dementia) (Ganguli et al. 2011), and a proportion of patients may even revert to normal (2% (Petersen et al. 2010) to 31% (Palmer et al. 2010) depending on the MCI criteria used and design of the study); reverse conversions occur mainly in populationbased studies (Bruscoli and Lovestone 2004).”
BackgroundMethodEFNS guidelines for the diagnosis and management of Alzheimer's disease
Hort, J., O’Brien, J. T., Gainotti, G., Pirttila, T., Popescu, B. O., Rektorova, I., Sorbi, S., Scheltens, P., & Dementia, O. B. O. T. E. S. P. O. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03040.x · Cited by 490 · cited 5×
“2011) and European (Hort et al. 2010; Sorbi et al. 2012) clinical practice guidelines on the diagnosis and management of AD/dementia are available in various countries.”
BackgroundInfluentialSelf-citationSkrobot, O. A., Black, S. E., Chen, C., DeCarli, C., Erkinjuntti, T., Ford, G. A., Kalaria, R. N., O'Brien, J., Pantoni, L., Pasquier, F., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.09.007 · Cited by 431 · cited 1×
“2018) as well as in the continuum of vascular cognitive impairment (Skrobot et al. 2018).”
BackgroundSelf-citationVitamin E for Alzheimer's dementia and mild cognitive impairment
Farina, N., Llewellyn, D., Isaac, M. G. E. K. N., & Tabet, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub5 · Cited by 413
Vellas, B., Coley, N., Ousset, P.-J., Berrut, G., Dartigues, J.-F., Dubois, B., Grandjean, H., Pasquier, F., Piette, F., Robert, P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70206-5 · Cited by 398 · cited 3×
“reported that five years of treatment with EGb 761R in adults aged 70 years or older who spontaneously reported memory complaints did not reduce the risk of progression to AD compared with placebo (Vellas et al. 2012).”
BackgroundMethodInfluentialGinkgo biloba extract: Mechanisms and clinical indications
Diamond, B. J., Shiflett, S. C., Feiwel, N., Matheis, R. J., Noskin, O., Richards, J. A., & Schoenberger, N. E. (2000) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/s0003-9993(00)90052-2 · Cited by 389 · cited 1×
“Unfortunately, in some countries, low-quality Ginkgo products are marketed as herbal dietary supplements; these products are essentially different from standardised, drug-quality extracts, such as EGb 761VR (Diamond et al. 2000).”
BackgroundPrevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage
Vos, S. J. B., Verhey, F., Frölich, L., Kornhuber, J., Wiltfang, J., Maier, W., Peters, O., Rüther, E., Nobili, F., Morbelli, S., et al. (2015) · Brain · doi:10.1093/brain/awv029 · Cited by 383 · cited 2×
“Operational use of biomarker evidence for amyloid pathology and neuronal injury allows to differentially assess the likelihood of progression to AD dementia at the MCI stage (Vos et al. 2015).”
BackgroundSelf-citationLi, J.-Q., Tan, L., Wang, H.-F., Tan, M.-S., Tan, L., Xu, W., Zhao, Q.-F., Wang, J., Jiang, T., & Yu, J.-T. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-310095 · Cited by 359 · cited 1×
“Additionally, biological and epidemiological risk factors of disease progression from MCI to dementia have been identified, including apolipoprotein E4 (APOE-e4), depression, loneliness, hearing impairment, diabetes, hypertension, older age, female gender and stronger cognitive impairment as reflected by lower mini-me…”
BackgroundO’Brien, J. T., Holmes, C., Jones, M., Jones, R., Livingston, G., McKeith, I., Mittler, P., Passmore, P., Ritchie, C., Robinson, L., et al. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116680924 · Cited by 354
Feldman, H. H., Ferris, S., Winblad, B., Sfikas, N., Mancione, L., He, Y., Tekin, S., Burns, A., Cummings, J., del Ser, T., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70109-6 · Cited by 335 · cited 1×
“For dementia prevention, evidence from the literature does not support the use of any studied intervention to date (Brasure et al. 2018; Butler, McCreedy, et al. 2018; Butler, Nelson, et al. 2018; Fink et al. 2018).”
MethodDrugs for Alzheimer's disease: are they effective?
Casey, D., Antimisiaris, D. E., & O’Brien, J. G. (2010) · PubMed Central · Cited by 332
Ueda, T., Suzukamo, Y., Sato, M., & Izumi, S.-I. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.02.003 · Cited by 330 · cited 1×
“Psychotherapeutic interventions were not discussed in this paper, but their value for helping patients with cognitive impairments cope with the burden these ailments bring about in daily life has been examined elsewhere (Ueda et al. 2013; Simon et al. 2015).”
BackgroundPlasma nutrient status of patients with Alzheimer's disease: Systematic review and meta‐analysis
Lopes da Silva, S., Vellas, B., Elemans, S., Luchsinger, J., Kamphuis, P., Yaffe, K., Sijben, J., Groenendijk, M., & Stijnen, T. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.05.1771 · Cited by 311
EFNS‐ENS Guidelines on the diagnosis and management of disorders associated with dementia
Sorbi, S., Hort, J., Erkinjuntti, T., Fladby, T., Gainotti, G., Gurvit, H., Nacmias, B., Pasquier, F., Popescu, B. O., Rektorova, I., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03784.x · Cited by 306 · cited 5×
“2011) and European (Hort et al. 2010; Sorbi et al. 2012) clinical practice guidelines on the diagnosis and management of AD/dementia are available in various countries.”
BackgroundInfluentialSelf-citationEfficacy of donepezil in mild cognitive impairment: A randomized placebo-controlled trial
Salloway, S., Ferris, S., Kluger, A., Goldman, R., Griesing, T., Kumar, D., & Richardson, S. (2004) · Neurology · doi:10.1212/01.wnl.0000134664.80320.92 · Cited by 300
A Systematic Review of Neuropsychiatric Symptoms in Mild Cognitive Impairment
Monastero, R., Mangialasche, F., Camarda, C., Ercolani, S., & Camarda, R. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1120 · Cited by 298 · cited 1×
“Depression, apathy and anxiety have been reported to occur in 40% of adults with MCI (Monastero et al. 2009; Gallagher et al. 2017).”
BackgroundSinn, N., Milte, C. M., Street, S. J., Buckley, J. D., Coates, A. M., Petkov, J., & Howe, P. R. C. (2012) · British Journal of Nutrition · doi:10.1017/s0007114511004788 · Cited by 297 · cited 3×
“Sinn et al. (2012) conducted a six-month, double-blind, parallel RCT to investigate the benefits of supplementing the diet with docosahexaenoic acid (DHA)-rich and eicosapentaenoic acid (EPA)-rich fish oils for cognition, depressive symptoms and QoL in 50 elderly subjects (aged > 65 years) with MCI…”
BackgroundResultUffelen, J. G. Z. V., Chin A Paw, M. J. M., Hopman-Rock, M., & Mechelen, W. V. (2008) · Clinical Journal of Sport Medicine · doi:10.1097/jsm.0b013e3181845f0b · Cited by 296 · cited 1×
“A systematic review by van Uffelen et al. evaluating 23 RCTs, eight of which recruited MCI patients, reported modest benefits from exercise on several aspects of executive functions (van Uffelen et al. 2008).”
Palmer, K., Di Iulio, F., Varsi, A. E., Gianni, W., Sancesario, G., Caltagirone, C., & Spalletta, G. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1352 · Cited by 290 · cited 2×
“2010) to 31% (Palmer et al. 2010) depending on the MCI criteria used and design of the study); reverse conversions occur mainly in populationbased studies (Bruscoli and Lovestone 2004).”
BackgroundOutcomes of Mild Cognitive Impairment by Definition: A Population Study
Ganguli, M., Snitz, B. E., Saxton, J. A., Chang, C.-C. H., Lee, C.-W., Vander Bilt, J., Hughes, T. F., Loewenstein, D. A., Unverzagt, F. W., & Petersen, R. C. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.101 · Cited by 285 · cited 2×
“…(Roberts and Knopman 2013; Langa and Levine 2014), there are patients diagnosed with MCI who tend to remain stable (i.e. do not develop dementia) (Ganguli et al. 2011), and a proportion of patients may even revert to normal (2% (Petersen et al. 2010) to 31% (Palmer et al. 2010) depending on the…”
BackgroundSherman, D. S., Mauser, J., Nuno, M., & Sherzai, D. (2017) · Neuropsychology Review · doi:10.1007/s11065-017-9363-3 · Cited by 281 · cited 2×
“…the effect of multidomain lifestyle intervention strategies on the delay and/ or prevention of cognitive decline in older individuals with differentially increased risk for further cognitive decline (Ngandu et al. 2015; Andrieu et al. 2017; Sherman et al. 2017; Anderson-Hanley et al. 2018).”
BackgroundBrasure, M., Desai, P., Davila, H., Nelson, V. A., Calvert, C., Jutkowitz, E., Butler, M., Fink, H. A., Ratner, E., Hemmy, L. S., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m17-1528 · Cited by 280 · cited 1×
“For dementia prevention, evidence from the literature does not support the use of any studied intervention to date (Brasure et al. 2018; Butler, McCreedy, et al. 2018; Butler, Nelson, et al. 2018; Fink et al. 2018).”
Methodde Wilde, M. C., Overk, C. R., Sijben, J. W., & Masliah, E. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.12.005 · Cited by 278 · cited 1×
“Thus, based on the notion that cognitive decline in MCI is a result of, for example, the loss of synapses (de Wilde et al. 2016), a specific nutrient combination, Souvenaid was developed.”
BackgroundSafety and efficacy of galantamine in subjects with mild cognitive impairment
Winblad, B., Gauthier, S., Scinto, L., Feldman, H., Wilcock, G. K., Truyen, L., Mayorga, A. J., Wang, D., Brashear, H. R., Nye, J. S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000303815.69777.26 · Cited by 266 · cited 2×
“Non-significant delay of cognitive decline in MCI patients after two and four years, respectively, was revealed in clinical trials with galantamine (Winblad et al. 2008) and rivastigmine (Feldman et al. 2007).”
ResultSoininen, H., Solomon, A., Visser, P. J., Hendrix, S. B., Blennow, K., Kivipelto, M., Hartmann, T., Hallikainen, I., Hallikainen, M., Helisalmi, S., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30332-0 · Cited by 241 · cited 9×
“An EU-funded twoyear RCT (LipiDiDiet) investigated the effects of Souvenaid on cognitive decline (and related measures) in prodromal AD (Soininen et al. 2017).”
BackgroundMethodResultInfluentialSelf-citationDoes Cognitive Training Prevent Cognitive Decline?: A Systematic Review
Butler, M., McCreedy, E., Nelson, V. A., Desai, P., Ratner, E., Fink, H. A., Hemmy, L. S., McCarten, J. R., Barclay, T. R., Brasure, M., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m17-1531 · Cited by 236
Treatment for mild cognitive impairment: systematic review
Cooper, C., Li, R., Lyketsos, C., & Livingston, G. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.127811 · Cited by 229 · cited 2×
“A systematic review by Cooper et al. found no evidence from 41 RCTs that any specific treatment was effective in reducing the transition rate from MCI to dementia (Cooper et al. 2013).”
BackgroundRabin, J. S., Schultz, A. P., Hedden, T., Viswanathan, A., Marshall, G. A., Kilpatrick, E., Klein, H., Buckley, R. F., Yang, H.-S., Properzi, M., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1123 · Cited by 221
Mixed Dementia—the Most Common Cause of Dementia
KORCZYN, A. D. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04807.x · Cited by 219
Self-citationDonepezil treatment of patients with MCI: A 48-week randomized, placebo-controlled trial
Doody, R. S., Ferris, S. H., Salloway, S., Sun, Y., Goldman, R., Watkins, W. E., Xu, Y., & Murthy, A. K. (2009) · Neurology · doi:10.1212/01.wnl.0000344650.95823.03 · Cited by 213
Morris, G. P., Clark, I. A., & Vissel, B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1918-8 · Cited by 212 · cited 1×
“None of the large clinical trials with amyloid as a target have been successful to date, thus questioning the pharmacological relevance of this hypothesis at this stage of disease (Morris et al. 2018).”
BackgroundStröhle, A., Schmidt, D. K., Schultz, F., Fricke, N., Staden, T., Hellweg, R., Priller, J., Rapp, M. A., & Rieckmann, N. (2015) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2015.07.007 · Cited by 212 · cited 2×
“A meta-analysis by Strohle et al. reported small improvements in cognition of MCI patients with physical exercise (Strohle et al. 2015).”
BackgroundMethodDONEPEZIL TREATMENT OF PATIENTS WITH MCI: A 48-WEEK RANDOMIZED, PLACEBO- CONTROLLED TRIAL
Crane, P. K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bd6c25 · Cited by 195
Anderson-Hanley, C., Barcelos, N. M., Zimmerman, E. A., Gillen, R. W., Dunnam, M., Cohen, B. D., Yerokhin, V., Miller, K. E., Hayes, D. J., Arciero, P. J., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00076 · Cited by 187 · cited 2×
“…the effect of multidomain lifestyle intervention strategies on the delay and/ or prevention of cognitive decline in older individuals with differentially increased risk for further cognitive decline (Ngandu et al. 2015; Andrieu et al. 2017; Sherman et al. 2017; Anderson-Hanley et al. 2018).”
BackgroundFink, H. A., Jutkowitz, E., McCarten, J. R., Hemmy, L. S., Butler, M., Davila, H., Ratner, E., Calvert, C., Barclay, T. R., Brasure, M., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m17-1529 · Cited by 183 · cited 1×
“For dementia prevention, evidence from the literature does not support the use of any studied intervention to date (Brasure et al. 2018; Butler, McCreedy, et al. 2018; Butler, Nelson, et al. 2018; Fink et al. 2018).”
MethodQuality of life in patients with mild cognitive impairment
Bárrios, H., Narciso, S., Guerreiro, M., Maroco, J., Logsdon, R., & de Mendonça, A. (2013) · Aging & Mental Health · doi:10.1080/13607863.2012.747083 · Cited by 182 · cited 3×
“Notably, QoL is affected at early stages of cognitive decline (B arrios et al. 2013).”
BackgroundDonepezil for mild cognitive impairment
Birks, J., & Flicker, L. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006104 · Cited by 169 · cited 2×
“(2004), concluded that donepezil lacks efficacy in MCI patients (Salloway et al. 2004; Birks and Flicker 2006).”
BackgroundStites, S. D., Harkins, K., Rubright, J. D., & Karlawish, J. (2018) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000262 · Cited by 165 · cited 1×
“Cognitive complaints are associated with lower quality of life (QoL), a higher depression and anxiety rate, higher perceived stress and lower general mental well-being (Pusswald et al. 2015; Stites et al. 2018).”
BackgroundGallagher, D., Fischer, C. E., & Iaboni, A. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716648296 · Cited by 157 · cited 1×
“Depression, apathy and anxiety have been reported to occur in 40% of adults with MCI (Monastero et al. 2009; Gallagher et al. 2017).”
BackgroundLiu, X., Hao, W., Qin, Y., Decker, Y., Wang, X., Burkart, M., Schötz, K., Menger, M. D., Fassbender, K., & Liu, Y. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.01.011 · Cited by 149 · cited 2×
“…and in vitro experiments, EGb 761VR has demonstrated effects such as 1) improvement of mitochondrial function, 2) antioxidant effects, 3) enhancement of synaptic function and neuronal plasticity, 4) antiinflammatory effects and 5) improvement of blood flow (Liu et al. 2015; M€uller et al. 2017).”
BackgroundJak, A. J., Preis, S. R., Beiser, A. S., Seshadri, S., Wolf, P. A., Bondi, M. W., & Au, R. (2016) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617716000199 · Cited by 149 · cited 2×
“Different diagnostic criteria and subtypes of MCI have been proposed and modified over time (Table 1); (Ash and Korczyn 2011; Jak et al. 2016) these shifts reflect the evolving recognition of MCI as an early disease state in the Alzheimer’s disease (AD) continuum (Jack et al.”
BackgroundButler, M., Nelson, V. A., Davila, H., Ratner, E., Fink, H. A., Hemmy, L. S., McCarten, J. R., Barclay, T. R., Brasure, M., & Kane, R. L. (2018) · Annals of Internal Medicine · doi:10.7326/m17-1530 · Cited by 144
Kandiah, N., Ong, P. A., Yuda, T., Ng, L., Mamun, K., Merchant, R. A., Chen, C., Dominguez, J., Marasigan, S., Ampil, E., et al. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13095 · Cited by 143
Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease
Dubois, B., Chupin, M., Hampel, H., Lista, S., Cavedo, E., Croisile, B., Louis Tisserand, G., Touchon, J., Bonafe, A., Ousset, P. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.003 · Cited by 140 · cited 1×
“In a second RCT study by Dubois et al. (2015), prodromal AD patients treated with donepezil did not differ from controls in their rate of decline, although they showed significantly less shrinkage of the hippocampus (45% reduced rate of hippocampal atrophy) (Dubois et al. 2015).”
BackgroundSi, G., Preuss, U. W., Wong, J. W. M., Hoerr, R., Kaschel, R., Bachinskaya, N. Y., & the GIMCIPlus Study Group (2014) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4103 · Cited by 132 · cited 4×
“(240mg daily) for 24weeks improved NPS and cognitive performance (Gavrilova et al. 2014).”
BackgroundInfluentialPußwald, G., Tropper, E., Kryspin‐Exner, I., Moser, D., Klug, S. J., Auff, E., Dal‐Bianco, P., & Lehrner, J. P. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150284 · Cited by 132
Caregiver burden in mild cognitive impairment
Paradise, M., McCade, D., Hickie, I. B., Diamond, K., Lewis, S. J. G., & Naismith, S. L. (2014) · Aging & Mental Health · doi:10.1080/13607863.2014.915922 · Cited by 106
Karakaya, T., Fußer, F., Schroder, J., & Pantel, J. (2013) · Current Neuropharmacology · doi:10.2174/157015913804999487 · Cited by 102
Ihl, R., Frölich, L., Winblad, B., Schneider, L., Burns, A., Möller, H.-J., & WFSBP Task Force on Treatment Guidelines for Alzheimer's Disease and other Dementias (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.538083 · Cited by 97 · cited 8×
“EGb 761R has demonstrated efficacy in the cognitive function and neuropsychiatric symptoms of patients with AD, vascular and mixed dementia comparable to that of AChE-I or memantine, but with fewer side-effects (Ihl et al. 2011).”
BackgroundInfluentialSelf-citationvan Maurik, I. S., Zwan, M. D., Tijms, B. M., Bouwman, F. H., Teunissen, C. E., Scheltens, P., Wattjes, M. P., Barkhof, F., Berkhof, J., van der Flier, W. M., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.2712 · Cited by 90
Risperidone for Dementia-Related Disturbed Behavior in Nursing Home Residents: A Clinical Experience
Goldberg, R. J., & Goldberg, J. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004213 · Cited by 84
The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey
Bocchetta, M., Galluzzi, S., Kehoe, P. G., Aguera, E., Bernabei, R., Bullock, R., Ceccaldi, M., Dartigues, J., de Mendonça, A., Didic, M., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.006 · Cited by 76 · cited 1×
“In addition to a clinical diagnosis of MCI, the modified criteria proposed by the IWG and the NIA-AA include the presence of biomarkers indicative for AD pathophysiology; these criteria are commonly used in clinical practice in Europe for diagnosis and communication to MCI patients (Bocchetta et al. 2015; Bertens et a…”
MethodSelf-citationAshford, J. W. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150381 · Cited by 69
D’Cunha, N. M., Georgousopoulou, E. N., Dadigamuwage, L., Kellett, J., Panagiotakos, D. B., Thomas, J., McKune, A. J., Mellor, D. D., & Naumovski, N. (2018) · British Journal of Nutrition · doi:10.1017/s0007114517003452 · Cited by 68 · cited 2×
“In addition to the bioactive compounds in Souvenaid, a few other long-term studies with nutraceuticals, e.g. vitamin B and omega-3 fatty acids, report some positive effects of mitigating the cognitive decline in MCI patients (McAnany and Martirosyan 2016; D’Cunha et al. 2018).”
BackgroundHorr, T., Messinger-Rapport, B., & Pillai, J. A. (2015) · The Journal of nutrition, health and aging · doi:10.1007/s12603-014-0565-6 · Cited by 67 · cited 1×
“physical activity, cognitive training, and socialisation, among MCI subjects were beneficial (Horr et al. 2015).”
BackgroundMüller, W. E., Eckert, A., Eckert, G. P., Fink, H., Friedland, K., Gauthier, S. G., Hoerr, R., Ihl, R., Kasper, S. F., & Möller, H. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1308552 · Cited by 65
Self-citationGómez-Isla, T., Blesa, R., Boada, M., Clarimón, J., Ser, T. D., Domenech, G., Ferro, J. M., Gómez-Ansón, B., Manubens, J. M., Martínez-Lage, J. M., et al. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181611024 · Cited by 64 · cited 1×
“However, the trial was interrupted prematurely due to subject recruitment problems (Gomez-Isla et al. 2008).”
BackgroundSimon, S. S., Cordás, T. A., & Bottino, C. M. C. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4239 · Cited by 62 · cited 2×
“Psychotherapeutic interventions were not discussed in this paper, but their value for helping patients with cognitive impairments cope with the burden these ailments bring about in daily life has been examined elsewhere (Ueda et al. 2013; Simon et al. 2015).”
BackgroundEffects of Ginkgo Biloba Special Extract EGb 761® in Very Mild Cognitive Impairment (vMCI)
Grass‐Kapanke, B., Busmane, A., Lasmanis, A., Hoerr, R., & Kaschel, R. (2011) · Neuroscience & Medicine · doi:10.4236/nm.2011.21007 · Cited by 60 · cited 10×
“This trend for informants to rate QoL lower than patients is consistent with what is observed in more advanced stages of cognitive decline, i.e. dementia, and may beTa bl e 1.”
BackgroundInfluential(2013) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9780890425596.dsm17 · Cited by 57
A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI
Peters, O., Lorenz, D., Fesche, A., Schmidtke, K., Hüll, M., Perneczky, R., Rüther, E., Möller, H.-J., Jessen, F., Maier, W., et al. (2012) · The Journal of nutrition, health and aging · doi:10.1007/s12603-012-0062-8 · Cited by 55
Self-citationUse of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey
Bertens, D., Vos, S. J. B., Kehoe, P. G., Wolf, H., Nobili, F. M., de Mendonça, A., van Rossum, I., Hort, J., Molinuevo, J. L., Heneka, M. T., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0525-9 · Cited by 54 · cited 2×
“In addition to a clinical diagnosis of MCI, the modified criteria proposed by the IWG and the NIA-AA include the presence of biomarkers indicative for AD pathophysiology; these criteria are commonly used in clinical practice in Europe for diagnosis and communication to MCI patients (Bocchetta et al. 2015; Bertens et a…”
MethodSelf-citationPersonalized risk for clinical progression in cognitively normal subjects-the ABIDE project
Initiative, F. T. A. D. N., van Maurik, I. S., Slot, R. E. R., Verfaillie, S. C. J., Zwan, M. D., Bouwman, F. H., Prins, N. D., Teunissen, C. E., Scheltens, P., Barkhof, F., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0487-y · Cited by 47 · cited 1×
“Therefore, risk stratification and personalised prediction is a high priority (van Maurik et al. 2019).”
BackgroundA Survey of Patient and Partner Outcome and Treatment Preferences in Mild Cognitive Impairment
Smith, G. E., Chandler, M. J., Fields, J. A., Aakre, J. A., & Locke, D. E. C. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171161 · Cited by 43 · cited 1×
“In a recent survey of patient and partner outcome and treatment preferences, QoL was given the highest priority for MCI, whereas distressing behaviours and caregiver outcomes (burden, mood and self-efficacy) had lower rankings (Smith et al. 2018).”
BackgroundDe Beaumont, L., Study, T. A. D. C., Pelleieux, S., Lamarre-Théroux, L., Dea, D., & Poirier, J. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160373 · Cited by 41 · cited 1×
“Similarly, some benefit of donepezil was evident at the end of a three-year follow-up study among earlier-age AD onset carriers of APOE-E4 and the Kalow variant of butyrylcholinesterase (BChE-K) genes (De Beaumont et al. 2016).”
BackgroundGschwind, Y. J., Bridenbaugh, S. A., Reinhard, S., Granacher, U., Monsch, A. U., & Kressig, R. W. (2017) · Aging Clinical and Experimental Research · doi:10.1007/s40520-016-0699-y · Cited by 36 · cited 3×
“This GBE (120mg) administered twice daily in MCI patients aged 50–85 years improved dual-task-related gait performance in MCI patients (Gschwind et al. 2017).”
BackgroundInfluentialSelf-citationLessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target
Wang, Y., Yan, T., Lu, H.-H., Yin, W., Lin, B., Fan, W.-B., Zhang, X., & Fernandez-Funez, P. (2017) · Neurodegenerative Diseases · doi:10.1159/000478741 · Cited by 35 · cited 1×
“Since b-amyloid (Ab) has evolved as a potential major target for disease modification in AD, several compounds, e.g. beta- and gamma-secretase inhibitors and anti-amyloid antibodies have been investigated in ‘early AD’, i.e. in MCI up to mild dementia (Wang et al. 2017).”
BackgroundBurden of caregivers for patients with mild cognitive impairment in Japan
Hayashi, S., Terada, S., Nagao, S., Ikeda, C., Shindo, A., Oshima, E., Yokota, O., & Uchitomi, Y. (2013) · International Psychogeriatrics · doi:10.1017/s1041610213000537 · Cited by 30 · cited 1×
“Management of neurobehavioural symptoms may therefore be important to reduce the burden on caregivers of MCI patients (Hayashi et al. 2013).”
BackgroundScherrer, B., Andrieu, S., Ousset, P., Berrut, G., Dartigues, J. F., Dubois, B., Pasquier, F., Piette, F., Robert, P. H., Touchon, J., et al. (2015) · The journal of nutrition health & aging · doi:10.1007/s12603-015-0661-2 · Cited by 23 · cited 1×
“A protocol-specified subgroup analysis and a secondary analysis applying an appropriate statistical model for time-to-event data with non-proportionate hazards revealed a significant late-treatment effect (Scherrer et al. 2015).”
Is Amnestic Mild Cognitive Impairment a Useful Concept?
Ash, E. L., & Korczyn, A. D. (2011) · Aging Health · doi:10.2217/ahe.10.90 · Cited by 15
Self-citationDemenz vom Alzheimer-Typ: Nicht-medikamentöse und medikamentöse Therapie
Kressig, R. W. (2015) · Therapeutische Umschau · doi:10.1024/0040-5930/a000670 · Cited by 8
Self-citationThe effects of bioactive compounds on Alzheimer’s disease and mild cognitive impairment
McAnany, B., & Martirosyan, D. M. (2016) · Functional Foods in Health and Disease · doi:10.31989/ffhd.v6i6.257 · Cited by 8 · cited 2×
“In addition to the bioactive compounds in Souvenaid, a few other long-term studies with nutraceuticals, e.g. vitamin B and omega-3 fatty acids, report some positive effects of mitigating the cognitive decline in MCI patients (McAnany and Martirosyan 2016; D’Cunha et al. 2018).”
BackgroundMongil, R. L., Trigo, J. A. L., Lázaro, A. M., Chaín, G. M., Cordero, P. R., & Sanmartí, L. S. (2017) · Revista Española de Geriatría y Gerontología · doi:10.1016/s0211-139x(18)30086-6 · Cited by 8
Joachim, L. K., Frölich, L., Rüther, E., Wiltfang, J., Maier, W., Kornhuber, J., Bauer, C., Heuser, I., & Peters, O. (2018) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.5 · Cited by 8 · cited 1×
“The authors of this study concluded that testing symptomatic treatment effects of such pharmacological agents in future MCI clinical trials should include the assessment of biomarkers to enrol patients with abnormal target biomarker profiles (Joachim et al. 2018).”
BackgroundSelf-citation
Cited by
Cai, M., Chen, S., Du, Y., Li, S., Dong, P., Wang, L., Yang, R., Hu, J., & Zhu, L. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-02052-4 · Cited by 4
Metadata
- Authors
- Kasper, S., Bancher, C., Eckert, A., Förstl, H., Frölich, L., Hort, J., Korczyn, A. D., Kressig, R. W., Levin, O., & Palomo, M. S. M.
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2020-02-05
- Volume
- 21
- Issue
- 8
- Pages
- 579-594
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W3005048617
- Cited by
- 233
- References
- 97
- FWCI
- 15.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.